Spontaneous Iliopsoas Muscle Hemorrhage Secondary to Ibrutinib (Imbruvica; Pharmacyclics): Brief Report. (5th May 2016)

• Record Type: Journal Article
• Authors: Sarcon, Anna; Botta, Gregory P.; Patel, Nikunj; Saven, Alan
• Is Part Of: Journal of investigative medicine high impact case reports. Volume 4:Number 2(2016)
• Publication Date: 2016-05-05
• Subjects: hemorrhage -- Imbruvica -- iliopsoas muscle; Internal medicine -- Periodicals; Medical care -- Periodicals; 616.005
• DOI: 10.1177/2324709616648457
• Languages: English
• ISSNs: 2324-7096

Abstract

Ibrutinib (Imbruvica; Pharmacyclics) is the first Food and Drug Administration–approved inhibitor of Burton's tyrosine kinase (BTK). Attenuation of BTK signaling ultimately leads to inhibition of B-cell proliferation and apoptosis. After a series of clinical trials, the Food and Drug Administration approved ibrutinib in patients with relapsed chronic lymphocytic leukemia in 2014 and Waldenström's macroglobulinemia in 2015. Those trials included rare grade 3+ hemorrhagic events associated with ibrutinib. Herein, we report a unique presentation of back pain due to iliopsoas muscle hemorrhage in a patient with Waldenström's macroglobulinemia after initiation of ibrutinib.